Serum Institute of India (SII) re-starts COVAX exports; passes 1billion COVISHIELD dose
:: Total number of COVISHIELD doses produced now surpasses 1.25bn mark.
:: Resumption of global distribution of COVISHIELD via the COVAX mechanism and to low- and middle-income countries.
Pune, 26th November, 2021: Serum Institute of India (SII) today announces it has resumed exports to the international vaccine sharing programme COVAX. The first batches of its COVISHIELD COVID-19 vaccine left the SII manufacturing facility in Pune earlier today, for distribution to low- and middle-income countries via the COVAX mechanism. SII’s supply of doses via COVAX is expected to increase substantially into Quarter 1 2022.
The resumption of exports is linked to SII surpassing its original target to produce 1bn doses of COVISHIELD by the end of this year. SII has reached this milestone ahead of time via rapid expansion of production capacity at its site in Pune.
To bolster its COVID-19 vaccine output even further, SII will bring into production other vaccines under licence. These include COVOVAX, from US-based company Novavax, which received its first Emergency Use Authorisations (EUAs) from regulators in Indonesia and the Philippines this month. Further regulatory reviews are pending for COVOVAX in India and with the World Health Organization, and Novavax has also submitted several additional regulatory filings for its vaccine around the world…
…Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance which leads the COVAX Facility said: “The resumption of supplies from Serum Institute of India is an important development for COVAX as it enters its busiest period yet for shipping vaccines to participating economies. While COVAX’s portfolio is now much more diversified than it was earlier this year when we received our first SII deliveries, COVISHIELD remains an important product which has the potential to help us protect hundreds of millions of people in the months ahead.”…
…Throughout the pandemic, SII has also been able to maintain its supply of non-COVID-19 vaccines to low- and middle-income countries, including vaccines for polio, measles and pneumococcal disease.